NiKem Research and Dualsystems Biotech announce a Strategic Alliance

The ever increasing complexity and expense of drug discovery requires an excellent understanding of molecular targets and mechanism of action in disease early in the research phase to match high quality compound optimisation. Dualsystems offers a proprietary suite of technologies for drug and target profiling from a client’s phenotypic assays. Based on its advanced platforms to discover protein interactions, mechanism of action and target network, information is generated at an early stage of hit-to-lead, lead optimisation or candidate selection.

These skills are complemented by the synthetic and medicinal chemistry expertise, the ADMET & DMPK and early toxicology services that NiKem has been providing to its clients over the last 10 years. The combined skills that Dualsystems and NiKem can now offer via a single point of contact make for a highly efficient drug discovery engine. All generated intellectual property is assigned to the client.

Dualsystems’ and NiKem’s combined technologies will help clients speed up their drug development by providing real-time information about drug candidates, their targets, their mechanisms of action and allow for a seamless downstream development of the molecules of interest.

Dualsystems is a spin-off from the University Zurich, Switzerland. It was awarded with the CTI Start-up Label in 2000.